Improved Insulin Sensitivity by GLUT12 Overexpression in Mice by Purcell, Scott H. et al.
Improved Insulin Sensitivity by GLUT12
Overexpression in Mice
Scott H. Purcell,
1 Lauren B. Aerni-Flessner,
1 Alexandra R. Willcockson,
1 Kelly A. Diggs-Andrews,
2
Simon J. Fisher,
2 and Kelle H. Moley
1
OBJECTIVE—Evidence suggests that insulin-sensitive glucose
transporters (GLUTs) other than GLUT4 may exist. To investigate
whether GLUT12 may represent another insulin-sensitive GLUT,
transgenic (TG) mice that overexpress GLUT12 were characterized.
RESEARCH DESIGN AND METHODS—TG mice that over-
expressed GLUT12 under a b-actin promoter were generated. Glu-
cose metabolism in TG and wild-type control mice was compared
using glucose and insulin tolerance tests and hyperinsulinemic-
euglycemic clamps. In addition, basal and insulin-stimulated glu-
cose clearance rates into insulin-sensitive peripheral tissues were
measured using [
3H]-2-deoxy-D-glucose.
RESULTS—GLUT12 was overexpressed by 40–75% in TG com-
pared with wild-type mice in insulin-sensitive tissues with no
change in GLUT4 content. Body weight and fasting blood glucose
did not differ between wild-type and TG mice; however, insulin
concentrations were reduced in TG mice. Enhanced oral glucose
tolerance was noted in TG mice by a reduced blood glucose
excursion compared with wild-type mice (P , 0.05). Enhanced
insulin sensitivity was noted by a greater decrease in blood glucose
in TG mice during insulin tolerance testing. Hyperinsulinemic-
euglycemic clamps conﬁrmed enhanced insulin sensitivity in
GLUT12-overexpressing mice (P , 0.01). Tissues of TG mice
exhibited normal basal glucose clearance rates; however, under
insulin-stimulated conditions, glucose clearance was signiﬁcantly
increased (P , 0.01) in tissues of TG mice.
CONCLUSIONS—Increased expression of GLUT12 results in
improved whole-body insulin sensitivity mediated by an in-
creased glucose clearance rate in insulin-responsive tissues
under insulin-stimulated, but not basal, conditions. These ﬁndings
provide evidence that GLUT12 represents a novel, second insulin-
sensitive GLUT. Diabetes 60:1478–1482, 2011
T
he glucose transporter (GLUT) responsible for
insulin-stimulated glucose uptake in peripheral
tissues, such as skeletal muscle and fat, is
GLUT4. Interestingly, the GLUT4 knockout
mouse does not develop hyperglycemia (1), and soleus
muscle from GLUT4 knockout mice retains its ability to
increase glucose uptake in response to insulin (2). These
ﬁndings have led to an interest in identifying other insulin-
sensitive GLUTs. The class III facilitative GLUT, GLUT12,
was ﬁrst identiﬁed by Rogers et al. (3) in MCF7 cells.
Experiments in Xenopus oocytes showed that GLUT12
preferentially transported D-glucose and 2-deoxy-D-glucose
over other hexoses (4). The presence of targeting motifs
similar to GLUT4 and GLUT8 (5,6), and localization pri-
marily in insulin-sensitive tissues (6–10), has led to re-
search into whether GLUT12 may represent a second
insulin-sensitive GLUT. Stuart et al. (11) recently demon-
strated that in human skeletal muscle, GLUT12 trans-
locates to the plasma membrane following euglycemic
insulin infusion. The authors also reported that insulin-
induced GLUT12 translocation to the plasma membrane in
L6 cells required phosphatidyl inositol-3 kinase activity.
To further assess the function of GLUT12 as an insulin-
sensitive GLUT, transgenic (TG) mice were generated
to study the effects of GLUT12 overexpression on whole-
animal glucose homeostasis and insulin-stimulated glucose
clearance into peripheral tissues.
RESEARCH DESIGN AND METHODS
TGmice.TheopenreadingframeofmurineGLUT12cDNAwasclonedfroman
ES cell line, and a FLAG-tag was inserted at the amino terminus of GLUT12.
FLAG-mGLUT12 was veriﬁed by sequencing and ligated into the pBAP ex-
pression vector containing 3 kb of the human b-actin promoter (12). This
construct was injected into the pronuclei of FVB/NJ oocytes. TG animals were
identiﬁed by PCR ampliﬁcation of tail DNA using the following primers: for-
ward: 59-CGA CCA GTG TTT GCC TTT TA 239 and reverse: 59-TGA TGG CTG
CAG TAA CAG ATG 239, which amplify a 474-bp fragment. Two founder lines
(TG-A and TG-B) were selected for additional study on the basis of the
GLUT12 expression level (Supplementary Fig. 1). Homozygous animals were
identiﬁed by crossing TG mice to wild-type FVB/NJ mice and genotyping the
F1 litters using the primers described above. Homozygous breeding pairs were
then used to obtain mice in all studies. To ensure that experimental results
were not a result of nonspeciﬁc transgene interference in physiology, initial
phenotyping experiments were conﬁrmed in a second line of TG mice (TG-B)
(Supplementary Table 1 and Supplementary Fig. 2). All experiments were
performed on male mice at 6–7 weeks of age. All animal procedures were
approved by the Washington University School of Medicine Animal Studies
Committee.
Westernblots.Westernblotswereperformedonvarioustissues,aspreviously
described (9), using the following primary antibodies: rabbit anti-GLUT12
(1:1,000) generated in the laboratory (6,9), rabbit anti-GLUT4 (1:2,000) pro-
vided by Dr. Michael Mueckler (Washington University), and mouse anti–
b-actin (1:5,000; Millipore, Billerica, MA). Secondary goat anti-rabbit IR Dye
800 or goat anti-mouse IR Dye 680 antibodies (LI-COR Biosciences, Lincoln,
NE) were used at 1:10,000 dilution for 1 h at room temperature. Membranes
were quantiﬁed using the Odyssey ﬂuorescent imager (LI-COR Biosciences).
Expression was quantiﬁed based on n = 4 for each tissue.
Fasting glucose and insulin concentrations. Blood glucose and plasma
insulin concentrations were measured in wild-type (n = 12) and TG (n =1 3 )
mice after a 16-h fast. Glucose was measured using a Contour TS glucometer
(Bayer Health Care, Tarrytown, NY); insulin was measured using an insulin
ELISA kit (Alpco Diagnostics, Salem, NH).
Glucose and insulin tolerance tests. For the glucose tolerance test (GTT),
wild-type (n = 12) and TG (n = 13) mice were fasted 16 h prior to an oral
gavage of 30% D-glucose (2 mg/g body wt; Sigma). Blood glucose was mea-
sured at 0, 30, 60, and 120 min via the tail vein. For the insulin tolerance test
(ITT), wild-type (n = 17) and TG (n = 15) mice were fasted 3 h prior to an
intraperitoneal injection of bovine insulin (0.75 mU/g body wt; Sigma). Blood
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BRIEF REPORTglucose was measured at 0, 15, 30, 45, and 60 min via the tail vein. For the ITT,
the percentage decrease in blood glucose from the 0 min time point was
calculated.
Hyperinsulinemic-euglycemic clamps. Animals were anesthetized and
catheters inserted into the jugular vein and femoral artery as previously de-
scribed (13). After 4–6 days of recovery, mice that had regained .90% of their
preoperative weight were used (n = 5 wild-type; n = 6 TG). All clamps began
5 h after food removal in awake, unrestrained mice. Insulin (Humulin R; Eli
Lilly, Indianapolis, IN) was infused at a constant rate of 20 mU $ kg
21 $ min
21.
Euglycemia was maintained at 80–100 mg/dL by infusion of variable rates of
50% dextrose (Hospira, Lake Forest, IL). Blood samples (~2 mL) were taken
from the arterial catheter at 10-min intervals for at least 1 h or until euglycemia
was maintained at least 30 min. During steady-state glucose infusion, a 20-mL
blood sample was taken to assay plasma insulin (Singlulex, Hayward, CA).
Average glucose concentrations and glucose infusion rates were measured
during the last 30 min of the steady-state clamp period.
Tissue-speciﬁc assessment of metabolic clearance rates for glucose.
Tissue-speciﬁc metabolic clearance rate (MCR) of glucose was measured using
[1,2-
3H]-2-deoxy-D-glucose ([
3H]-2DG; MP Biomedicals, Solon, OH) during
basal conditions and, in a separate group of mice, during the ﬁnal 30 min of the
hyperinsulinemic clamp. For basal determinations, mice (n = 5 wild-type; n =4
TG), recovered from catheterization as described above, were fasted for 5 h
and then blood glucose was measured prior to administration of a [
3H]-2DG
bolus. Weights were not different between wild-type and TG mice used during
basal or clamp conditions. In both basal and hyperinsulinemic clamp conditions,
a5 - mCi bolus of [
3H]-2DG was administered through the venous catheter.
FIG. 1. Representative Western blots and densitometry calculations of wild-type (WT) and TG mice. A: For each lane, 30 mg of protein was loaded
and blotted using antibodies against GLUT12 (1:1,000) and normalized to b-actin (1:5,000). B: For each lane, 10 mg of protein was loaded and
blotted using antibodies for GLUT4 (1:2,000) and normalized to b-actin (1:5,000). *P < 0.05 vs. wild-type mice.
S.H. PURCELL AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1479Blood samples were collected at 1, 5, 10, 15, 20, 25, and 30 min from the ar-
terial catheter following [
3H]-2DG injection for measurement of plasma glu-
cose and plasma [
3H]-2DG. Plasma glucose was measured using the Inﬁnity
Glucose Hexokinase reagent (Thermo-Fisher Scientiﬁc, Middletown, VA). At
the end of 30 min, mice were killed and extensor digitalis longus (EDL), so-




3H]-2DG-6P) were separated by
ion-exchange chromatography (AG 1-X8 Resin 100–200; Biorad, Hercules, CA)
and [
3H]-2DG-6P activity was counted. Tissue-speciﬁc MCRs (mL/g/min) of
plasma glucose were calculated from tissue [
3H]-2DG-6P content normalized
to the area under the plasma [
3H]-2DG decay curve divided by plasma glucose
concentration, as previously described (14–16).
Statistical analysis. Experimental results are shown as means 6 SE. For
GTTs and ITTs, differences across time points were assessed using ANOVA
and Tukey analysis. Because of the heterogeneity of variances in MCR values
across tissue types, log-transformed MCR data were used for ANOVA analysis.
RESULTS
Western blots. In most tissues tested (Fig. 1A), GLUT12
was detected at signiﬁcantly greater concentration in TG
than in wild-type mice. On the basis of GLUT12 values
normalized to actin, overexpression was greatest in brain
and heart, followed by soleus, fat, EDL, and liver. In the
insulin-sensitive tissues used for studies of tissue MCR,
increased GLUT12 expression ranged from 40% in the EDL
to 75% in the heart. Overexpression of GLUT12 did not
alter expression of GLUT4, as assessed by Western blot-
ting in skeletal muscle and fat (Fig. 1B).
Metabolic characteristics of TG mice. Fasting blood
glucose was not different between wild-type and TG mice
(79 vs. 82 mg/dL, respectively); however, insulin concen-
trations were reduced (P , 0.05) in TG mice (0.230 vs.
0.146 ng/mL, respectively). During the GTT, blood glucose
did not differ between wild-type and TG mice up to 30 min;
however, TG mice exhibited a more rapid normalization
(P , 0.05) of blood glucose at 60 min and continuing to
120 min (Fig. 2A). Improved insulin sensitivity in response
to an ITT (Fig. 2B) was noted because TG mice had
ag r e a t e r( P , 0.05) decrease in blood glucose concentra-
tion at 30 and 45 min after the insulin injection.
Hyperinsulinemic-euglycemic clamp and tissue glucose
clearance rates. Mice that overexpress GLUT12 required
a 70% greater (P , 0.01) glucose infusion rate (GIR) than
wild-type mice (Table 1) to maintain an equal degree of
euglycemia during the clamp. To assess both basal and
insulin-stimulated tissue-speciﬁc MCR of glucose, a [
3H]-2DG
tracer was used. Under basal conditions, blood glucose and
glucose MCR was not different between wild-type and TG
mice (Fig. 3). During clamp conditions, glucose clearance
increased in response to insulin infusion, but notably the TG
mice had signiﬁcantly greater MCR than wild-type mice
(P , 0.01) (Fig. 3). In EDL, TG mice exhibited a 23.8-fold
increase in MCR during clamp conditions compared with
basal conditions, whereas wild-type mice only exhibited
a 10.9-fold increase (Fig. 3A). In soleus, TG mice exhibited a
12.0-fold increase in MCR under clamp conditions versus
a 6.0-fold increase in wild-type mice (Fig. 3B). In fat, TG
mice exhibited a 2.9-fold increase in insulin-stimulated MCR
versus a 1.5-fold increase in wild-type mice (Fig. 3C). In
heart, TG and wild-type mice exhibited similar insulin-
stimulated MCR (Fig. 3D).
DISCUSSION
The objective of this study was to examine the effect of
GLUT12 overexpression in mediating glucose homeostasis
under basal and insulin-stimulated conditions. Importantly,
the ﬁndings are attributable to GLUT12 overexpression
because expression of the established insulin-sensitive
GLUT, GLUT4, was not altered. GLUT12 overexpression
did not affect fasting glucose but did decrease fasting in-
sulin, suggesting improved insulin sensitivity. Compared
with wild-type mice, TG mice demonstrated improved
glucose tolerance, consistent with enhanced insulin sen-
sitivity. Enhanced insulin sensitivity was more directly
shown in the ITT. The hyperinsulinemic-euglycemic clamp
conﬁrmed enhanced insulin sensitivity because GLUT12-
overexpressing mice required a 70% greater GIR to main-
tain euglycemia. Similar to our current study, GLUT4
overexpression in skeletal muscle and fat resulted in lower
basal insulin, decreased glycemic excursion during GTT
testing (17), and increased insulin sensitivity during a
hyperinsulinemic-euglycemic clamp (18). However, unlike
GLUT12 overexpression, GLUT4 overexpression increased
basal glucose uptake into isolated muscles and adipocytes
FIG. 2. GTTs and ITTs on wild-type (●) and TG (○) mice. A: Following
a 16-h fast, oral GTTs performed using 2 mg glucose per g of weight
(wild-type, n = 17; TG, n = 15). Data represent means 6 SE. *P < 0.05
vs. wild-type mice. B: ITT after a 3-h fast using 0.75 mU bovine insulin
per g of weight (wild-type, n = 12; TG, n = 13). Data represent the mean
percentage drop in blood glucose from the 0 min time point 6 SE. *P <
0.05 vs. wild-type mice.
TABLE 1
Metabolic parameters during the hyperinsulinemic-euglycemic
clamp experiment
Wild-type mice TG mice
n 65
Blood glucose (mg/dL) 92.8 6 3.2 90.9 6 5.7
GIR (mg/kg/min) 83.1 6 5.5 141.6 6 21.6*
Insulin (ng/mL) 14.9 6 1.7 11.2 6 2.0
Data are means 6 SE. *P , 0.01 vs. wild type.
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trations (17–19).
Our results indicated that GLUT12 overexpression in-
creased insulin-stimulated glucose uptake into peripheral
tissues. We sought to conﬁrm this observation and de-
termine whether GLUT12 overexpression caused an in-
creased rate of tissue glucose clearance under basal
conditions or only during insulin-stimulated conditions.
Consistent with the notion that GLUT12 is an insulin-
dependent GLUT and not a constitutively active GLUT,
glucose clearance rates were similar in TG and wild-type
mice under basal (non–insulin-stimulated) conditions. Dif-
ferences in glucose clearance were only observed during
the hyperinsulinemic clamp. As expected, glucose clear-
ance increased in response to insulin infusion, but notably
t h eT Gm i c eh a ds i g n i ﬁcantly greater (P , 0.01) MCR
than wild-type mice. Enhanced GLUT12-mediated glucose
clearance demonstrated tissue speciﬁcity. In response to
insulin infusion, glucose clearance was consistently twofold
greater in TG versus wild-type mice in EDL, soleus, and fat
but not in heart, despite the relatively higher degree of car-
diac GLUT12 overexpression. Per gram of tissue, insulin-
stimulated glucose clearance was greatest in the heart,
followed by skeletal muscle and then adipose, but the
heart’s fold increase of MCR in response to insulin infusion
was less than skeletal muscle, consistent with previous
studies (20–23).
In summary, GLUT12 overexpression in mice leads to
increased peripheral insulin sensitivity as determined by
1) reduced fasted insulin levels, 2) decreased glycemic
excursion during a GTT, 3) enhanced reduction of blood
glucose during an ITT, 4) increased GIR during a
hyperinsulinemic-euglycemic clamp, and 5) enhanced tissue-
speciﬁc glucose clearance. Importantly, enhanced glucose
clearance in insulin-sensitive peripheral tissues was noted
during insulin-stimulated conditions but not during basal
conditions. These are the ﬁrst studies to provide metabolic
evidence of GLUT12 function in an insulin-dependent
manner in a TG model. The studies described here provide
more detailed evidence that GLUT12 may represent a
novel, second insulin-sensitive GLUT.
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